Revance is a biotechnology company developing treatments based on the toxin that causes botulism for wrinkles and other conditions. The company hopes those treatments will improve on the popular Botox, also based on the same toxin.
The Newark, Calif.-based company raised $96 million offering 6 million shares at $16 each. It plans to use the proceeds to pay for research and development costs, clinical trials and other purposes.
Shares, trading under the symbol "RVNC" on the Nasdaq, jumped $10.85, or 68 percent, to $26.85.
Revance Therapeutics, Inc. is a United States-based specialty biopharmaceutical company. The Company develops botulinum toxin products for use in aesthetic and therapeutic indications. The Company has developed a platform technology, TransMTS, which enables local, targeted delivery of botulinum toxin and other macromolecules across skin without patches. The Company's investigational product is a topically applied botulinum toxin type A (BoNTA). Its investigational product, RT001 (botulinum toxin type A) Topical Gel, is designed to reduce crow's feet wrinkles by relaxing the muscles around the eye. RT001, a topically applied botulinum toxin type A, is under investigation for the treatment of hyperhidrosis, or excessive sweating.
Address
7555 Gateway Boulevard
NEWARK, CA 94560
United States
NEWARK, CA 94560
United States
No comments:
Post a Comment